HK2 and hepatocellular carcinoma: The newly identified HK2‐acyl‐CoA synthetase long chain family member 4 (ACSL4)‐fatty acid β‐oxidation axis is an ideal therapeutic target for hepatocellular carcinoma (HCC), and GalNac‐conjugated siHK2 opens an avenue to develop a novel strategy of precision therapy for the treatment of HCC.